- Home
- AREC vs BDTX Comparison
AREC vs BDTX Comparison
Compare AREC & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AREC | BDTX |
|---|---|---|
| Founded | 2013 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Coal Mining | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 206.5M | 171.9M |
| IPO Year | 2013 | 2020 |
Fundamental Metrics
Financial Performance| Metric | AREC | BDTX |
|---|---|---|
| Price | $2.69 | $2.08 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | $6.50 | ★ $9.67 |
| AVG Volume (30 Days) | ★ 2.3M | 602.5K |
| Earning Date | 06-01-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 223.53 | 130.71 |
| EPS | ★ 0.63 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $38,462.50 | N/A |
| P/E Ratio | $4.65 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.18 | $1.60 |
| 52 Week High | $7.11 | $4.94 |
Technical Indicators
Market Signals| Indicator | AREC | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 64.73 | 60.70 |
| Support Level | $2.52 | $1.96 |
| Resistance Level | $2.82 | $2.26 |
| Average True Range (ATR) | 0.20 | 0.10 |
| MACD | 0.07 | 0.03 |
| Stochastic Oscillator | 80.08 | 82.69 |
Price Performance
Historical ComparisonAbout AREC American Resources Corporation
American Resources Corp is engaged in the aggregation, recovery, recycling, and sale of recovered metal and steel materials. The company operates through two segments: Corporate and Electrified Materials. The Electrified Materials segment focuses on processing and recycling recovered metal and steel products.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.